Bavarian Nordic A/S Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, has completed an interim analysis of its first two clinical studies with MVA-BN®-HER2, a cancer vaccine immunotherapy for breast cancer patients.
The first study, performed in the US, is evaluating MVA-BN®-HER2 treatment following chemotherapy and Herceptin® treatment. In the second study, performed in Serbia and Poland, MVA-BN®-HER2 is being evaluated following only chemotherapy or in combination with single-agent taxane chemotherapy. Both studies evaluate treatment of metastatic breast cancer patients, whose tumors overexpress HER2. Patients are vaccinated 3 times, at 3 week intervals, with the MVA-BN® viral vector which has been engineered to express the extracellular fragment of human HER2.
With 27 out of 30 patients vaccinated, enrolment in the studies is nearly completed. No drug-related severe adverse events have been reported thus far. The vaccine has been shown to be well tolerated and immunogenic.
Immune evaluation of samples from 18 patients treated with MVA-BN®-HER2 revealed that 12 patients developed an immune response (humoral and/or cellular response).
These preliminary data show that MVA-BN®-based, HER2 directed vaccination is a biologically active treatment for patients with HER2 positive breast cancer. The final study data are expected around the turn of the year 2008/2009.
Anders Hedegaard, President & CEO of Bavarian Nordic, commented: "I am pleased that we once again can confirm the unique safety profile of MVA-BN® and that we have been able to show immunogenicity in this patient group suffering from this severe disease."
Kvistgård, 19 June 2008
Asger Aamund Chairman
Contact: Anders Hedegaard, President & CEO | +45 23 20 30 64
LINK: http://hugin.info/100065/R/1229149/260924.pdf
Bavarian Nordic A/S
http://www.bavarian-nordic.com
ISIN: DK0015998017
Stock Identifier: XCSE.BAVA
The first study, performed in the US, is evaluating MVA-BN®-HER2 treatment following chemotherapy and Herceptin® treatment. In the second study, performed in Serbia and Poland, MVA-BN®-HER2 is being evaluated following only chemotherapy or in combination with single-agent taxane chemotherapy. Both studies evaluate treatment of metastatic breast cancer patients, whose tumors overexpress HER2. Patients are vaccinated 3 times, at 3 week intervals, with the MVA-BN® viral vector which has been engineered to express the extracellular fragment of human HER2.
With 27 out of 30 patients vaccinated, enrolment in the studies is nearly completed. No drug-related severe adverse events have been reported thus far. The vaccine has been shown to be well tolerated and immunogenic.
Immune evaluation of samples from 18 patients treated with MVA-BN®-HER2 revealed that 12 patients developed an immune response (humoral and/or cellular response).
These preliminary data show that MVA-BN®-based, HER2 directed vaccination is a biologically active treatment for patients with HER2 positive breast cancer. The final study data are expected around the turn of the year 2008/2009.
Anders Hedegaard, President & CEO of Bavarian Nordic, commented: "I am pleased that we once again can confirm the unique safety profile of MVA-BN® and that we have been able to show immunogenicity in this patient group suffering from this severe disease."
Kvistgård, 19 June 2008
Asger Aamund Chairman
Contact: Anders Hedegaard, President & CEO | +45 23 20 30 64
LINK: http://hugin.info/100065/R/1229149/260924.pdf
Bavarian Nordic A/S
http://www.bavarian-nordic.com
ISIN: DK0015998017
Stock Identifier: XCSE.BAVA
| Tweet |
 |
Related Companies |
>>> Bavarian Nordic A/S |
| |
Related Industry Topics: |
European Finance News | |
| |
This Page Viewed: (Last 7 Days: 10) (Last 30 Days: 50) (Since Published: 4510) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
